AGM / EGM STATEMENTS
Valley Cottage, New York, October 2, 2007 - XTL Biopharmaceuticals Ltd.
(NASDAQ: XTLB; LSE: XTL; TASE: XTL) announces today that at its Annual General
Meeting and Extraordinary General Meeting held earlier today, all the
resolutions proposed to the shareholders were approved.
The cancellation of the listing of the Company's Ordinary Shares on the
Official List of the United Kingdom Listing Authority will take place at 8:00
am (London Time) on October 31, 2007.
ABOUT XTL BIOPHARMACEUTICALS LTD.
XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for
the treatment of diabetic neuropathic pain. XTL is also developing several
novel pre-clinical hepatitis C small molecule inhibitors. XTL also has an
active in-licensing and acquisition program designed to identify and acquire
additional drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).
Ron Bentsur, Chief Executive Officer
Tel: +1-(845)-267-0707 ext. 225